Gadoxetate Injectable Solution Suppliers & Bulk Manufacturers

Available Forms: Injectable Solution

Available Strengths: 0.25 mmol/mL

Reference Brands: Eovist(US)

Category: Contrast Agent

Gadoxetate is a gadolinium-based contrast agent that accumulates in liver cells, enhancing MRI images for detailed hepatobiliary assessment. It improves detection of liver lesions, supports early diagnosis, and aids in differentiating benign from malignant tumors. Benefits include high-resolution imaging, early detection, and accurate disease staging. Gadoxetate Injectable Solution is available in Injectable Solution and strengths such as 0.25 mmol/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Gadoxetate Injectable Solution is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Gadoxetate Injectable Solution can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Gadoxetate, marketed as Primovist in the EU and Eovist in the US, is approved for liver MRI by the EMA and FDA for hepatobiliary imaging. Regulatory approval requires a detailed dossier, including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and worldwide availability, supporting early diagnosis and optimal management of liver diseases across healthcare regions globally.